nivolumab
bms
['nadim ii', 'nadim', 'nsclc', 'lcsm,(-blcsm)', 'nivo', 'sclc']
nadim ii confirms neoadj nivo+chemo&gt;&gt;chemo in resectable stage iii nsclc. pcr (36.8% vs. 6.9%; or 7.88), tolerable safety, did not impede surgery. pdl1 tps predictive for pcr #asco22 #lcsm 
Thoracic Med Onc @MUSChealth @muschollings Charleston, South Carolina. Former Heme/Onc fellow @MontefioreNYC @EinsteinMed